BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1078 related articles for article (PubMed ID: 25665961)

  • 1. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
    Kawano Y; Suzuki M; Kawada J; Kimura H; Kamei H; Ohnishi Y; Ono Y; Uchida H; Ogura Y; Ito Y
    Vaccine; 2015 Mar; 33(12):1440-5. PubMed ID: 25665961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated data on effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation.
    Shinjoh M; Hoshino K; Takahashi T; Nakayama T
    Vaccine; 2015 Jan; 33(5):701-7. PubMed ID: 25510391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
    Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
    Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination vaccine against measles, mumps, rubella and varicella.
    Knuf M; Faber J; Barth I; Habermehl P
    Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.
    Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E
    Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.
    Feldman AG; Beaty BL; Ferrolino JA; Maron G; Weidner HK; Ali SA; Bitterfeld L; Boulware MA; Campbell KM; Carr E; Chapman S; Chang YC; Cunningham R; Dallas RH; Dantuluri KL; Domenick BN; Ebel NH; Elisofon S; Fawaz R; Foca M; Gans HA; Gopalareddy VV; Gu C; Gupta NA; Harmann K; Hollenbeck J; Huppler AR; Jaramillo C; Kasi N; Kerkar N; Lerret S; Lobritto SJ; Lopez MJ; Marini E; Mavis A; Mehra S; Moats L; Mohandas S; Munoz FM; Mysore KR; Onsan C; Ovchinsky N; Perkins K; Postma S; Pratscher L; Rand EB; Rowe RK; Schultz D; Sear K; Sell ML; Sharma T; Stoll J; Vang M; Villarin D; Weaver C; Wood P; Woodford-Berry O; Yanni G; Danziger-Isakov LA
    JAMA Netw Open; 2023 Oct; 6(10):e2337602. PubMed ID: 37824141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation.
    Shinjoh M; Miyairi I; Hoshino K; Takahashi T; Nakayama T
    Vaccine; 2008 Dec; 26(52):6859-63. PubMed ID: 18930096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Güris D; Chaves SS; Schmid S; Seward JF;
    MMWR Recomm Rep; 2007 Jun; 56(RR-4):1-40. PubMed ID: 17585291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
    Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
    Rüger G; Gabutti G; Rümke H; Rombo L; Bernaola E; Diez-Domingo J; Martinon-Torres F; Høgh B; Konstantopoulos A; Fiquet A; Thomas S; Eymin C; Baudin M
    Pediatr Infect Dis J; 2012 Nov; 31(11):1166-72. PubMed ID: 22772170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.